Pretreating multiple myeloma patients with Ethyol (amifostine) prior to a stem cell transplant significantly reduces the transplant therapy’s gastrointestinal toxicity without compromising its efficacy, a…
The Multiple Myeloma Research Foundation and Karyopharm Therapeutics are hoping that 2018 will be as momentous a year as 2017 in their collaborative effort to develop…
Multiple myeloma patients who received several prior lines of therapy showed promising response rates when treated with a combination of Karyopharm Therapeutics‘ selinexor…
A single injection of a new drug combination leads to faster and more effective harvesting of blood stem cells from bone marrow donors, a new mouse…
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…
A recent update on Cellectar Biosciences’ Phase 1 trial revealed that heavily treated myeloma patients who received the lowest dose of CLR 131 survived for a…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline’s investigational therapy GSK2857916 for the treatment of relapsed and refractory…
Health Canada has approved Imbruvica (ibrutinib) for the treatment of patients with steroid dependent or refractory chronic graft-versus-host disease (cGVHD), a life-threatening…
Cellectar Biosciences is expanding its Phase 1 dose-escalating trial to evaluate the effectiveness and safety of multiple administrations of CLR 131 for the treatment of relapsed…